A Major Breakthrough in Early Bladder Cancer Treatment
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). This landmark approval introduces the first immunotherapy-based combination regimen for this patient population in the United States.
The approval represents a significant advancement in bladder cancer treatment, offering new hope for patients who face a high risk of disease recurrence and progression.
Approval Backed by Positive POTOMAC Phase III Trial Results
The FDA’s decision is based on compelling results from the POTOMAC Phase III clinical trial. The study findings were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and later published in The Lancet.
Researchers evaluated the effectiveness of adding Imfinzi to standard BCG therapy in patients with BCG-naïve, high-risk NMIBC. The results demonstrated a substantial clinical benefit:
- 32% reduction in the risk of disease recurrence, progression, or death.
- Disease-free survival hazard ratio of 0.68 compared with BCG therapy alone.
- Median follow-up period exceeding five years (60.7 months).
- Consistent long-term disease-free survival benefits throughout the study period.
These findings indicate that combining immunotherapy with standard BCG treatment can significantly improve patient outcomes.
Strong Safety Profile Maintained
Safety remains a critical consideration in cancer treatment, and the POTOMAC trial delivered encouraging results in this area as well.
The safety profile of Imfinzi combined with BCG was consistent with the known safety characteristics of both therapies individually. Importantly:
- No new safety concerns were identified.
- Patients were able to complete their planned BCG treatment courses.
- Quality of life measures remained largely unaffected by the addition of Imfinzi.
These findings support the regimen’s suitability for routine clinical use in eligible patients.
What Is Non-Muscle-Invasive Bladder Cancer (NMIBC)?
Non-muscle-invasive bladder cancer is an early-stage form of bladder cancer that remains confined to the inner layers of the bladder wall and has not spread into the bladder muscle.
Although NMIBC is considered an early-stage disease, high-risk cases often experience recurrence and may progress to more aggressive forms of bladder cancer. Current standard treatment typically involves surgical tumor removal followed by BCG immunotherapy.
The addition of Imfinzi introduces a new therapeutic option aimed at reducing the likelihood of recurrence and improving long-term outcomes.
AstraZeneca’s Expanding Oncology Portfolio
The FDA approval further strengthens AstraZeneca’s growing presence in oncology and immunotherapy.
The company recently reported positive outcomes from several other bladder cancer studies, including:
- VOLGA Phase III trial in muscle-invasive bladder cancer.
- NIAGARA Phase III trial.
- NILE Phase III trial.
In addition, AstraZeneca and Daiichi Sankyo recently received FDA approval for Datroway (datopotamab deruxtecan) for the treatment of metastatic triple-negative breast cancer (TNBC).
Industry Perspective
Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Hematology Business Unit, highlighted the significance of the approval:
“Today’s approval for Imfinzi brings the first immunotherapy combination regimen to patients in the US with BCG-naïve, high-risk non-muscle-invasive bladder cancer. The early and sustained disease-free survival benefit demonstrated by Imfinzi plus BCG in the POTOMAC trial is an important advance for patients at risk of early disease recurrence and signals a shift in the standard of care.”
Global Regulatory Reviews Underway
Following the positive POTOMAC results, regulatory submissions for the Imfinzi-BCG combination are currently under review in the European Union, Japan, and several other countries.
If approved globally, the therapy could become a new standard treatment option for high-risk NMIBC patients worldwide.
Conclusion
The FDA approval of Imfinzi in combination with BCG marks a significant milestone in bladder cancer treatment. As the first approved immunotherapy combination for BCG-naïve, high-risk NMIBC patients, the regimen offers a meaningful reduction in recurrence and disease progression risk while maintaining a favorable safety profile.
With long-term clinical data supporting its effectiveness and additional regulatory reviews ongoing, Imfinzi plus BCG has the potential to reshape the treatment landscape for early-stage bladder cancer and improve outcomes for thousands of patients globally.
Recommended Products
